|
1
|
Pu Z, Yuan X, Zhang X, Chen Q and Xie H:
Meta-analysis on the association between CYP2D6*10 gene
polymorphism and disease free survival of breast cancer patients
receiving tamoxifen treatment in Asia. Bangladesh J Pharmacol.
9:652–662. 2014. View Article : Google Scholar
|
|
2
|
Couto P, Miranda D, Vieira R, Vilhena A,
De Marco L and Bastos-Rodrigues L: Association between CLOCK, PER3
and CCRN4L with non-small cell lung cancer in Brazilian patients.
Mol Med Rep. 10:435–440. 2014.PubMed/NCBI
|
|
3
|
Zhang HM, Yang FQ, Yan Y, Che JP and Zheng
JH: High expression of long non-coding RNA SPRY4-IT1 predicts poor
prognosis of clear cell renal cell carcinoma. Int J Clin Exp
Pathol. 7:5801–5809. 2014.PubMed/NCBI
|
|
4
|
Faltejskova P, Besse A, Sevcikova S,
Kubiczkova L, Svoboda M, Smarda J, Kiss I, Vyzula R and Slaby O:
Clinical correlations of miR-21 expression in colorectal cancer
patients and effects of its inhibition on DLD1 colon cancer cells.
Int J Colorectal Dis. 27:1401–1408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng J, Xue H, Wang T, Jiang Y, Liu B, Li
J, Liu Y, Wang W, Zhang B and Sun M: miR-21 downregulates the tumor
suppressor P12 CDK2AP1 and stimulates cell proliferation and
invasion. J Cell Biochem. 112:872–880. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu Y, Wang C, Li Y, Zhao J, Chen C, Zhou
Y, Tao Y, Guo M, Qin N, Ren T, et al: MiR-21 controls in situ
expansion of CCR6+ regulatory T cells through PTEN/AKT
pathway in breast cancer. Immunol Cell Biol. 93:753–764. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu Y, Yu X, Fu H, Wang H, Wang P, Zheng X
and Wang Y: MicroRNA-21 is involved in ionizing radiation-promoted
liver carcinogenesis. Int J Clin Exp Med. 3:211–222.
2010.PubMed/NCBI
|
|
8
|
Nassar FJ, El Sabban M, Zgheib NK, Tfayli
A, Boulos F, Jabbour M, El Saghir NS, Talhouk R, Bazarbachi A,
Calin GA, et al: miRNA as potential biomarkers of breast cancer in
the Lebanese population and in young women: A pilot study. PLoS
One. 9:e1075662014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang Y, Chen X, Tian W, Yin X, Wang J and
Yang H: The role of TGF-β1-miR-21-ROS pathway in bystander
responses induced by irradiated non-small-cell lung cancer cells.
Br J Cancer. 111:772–780. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kobayashi H, Ohno S, Sasaki Y and Matsuura
M: Hereditary breast and ovarian cancer susceptibility genes
(review). Oncol Rep. 30:1019–1029. 2013.PubMed/NCBI
|
|
11
|
Nishimura R, Arima N, Toyoshima S, Ohi Y,
Anan K, Sagara Y, Mitsuyama S and Tamura K: Evaluation of PTEN loss
and PIK3CA mutations and their correlation with efficacy of
trastuzumab treatment in HER2-positive metastatic breast cancer: A
retrospective study (KBC-SG 1001). Mol Clin Oncol. 1:47–52.
2013.PubMed/NCBI
|
|
12
|
Jiang N, Dong XP, Zhang SL, You QY, Jiang
XT and Zhao XG: Triptolide reverses the Taxol resistance of lung
adenocarcinoma by inhibiting the NF-kappaB signaling pathway and
the expression of NF-kappaB-regulated drug-resistant genes. Mol Med
Rep. Nov 2–2015.Epub ahead of print.
|
|
13
|
Zhou H, Guo W, Long C, Wang H, Wang J and
Sun X: Triptolide inhibits proliferation of Epstein-Barr
virus-positive B lymphocytes by down-regulating expression of a
viral protein LMP1. Biochem Biophys Res Commun. 456:815–820. 2015.
View Article : Google Scholar
|
|
14
|
Ho JN, Byun SS, Lee S, Oh JJ, Hong SK, Lee
SE and Yeon JS: Synergistic antitumor effect of triptolide and
cisplatin in cisplatin resistant human bladder cancer cells. J
Urol. 193:1016–1022. 2015. View Article : Google Scholar
|
|
15
|
Kriegshäuser G, Fabjani G, Ziegler B,
Zöchbauer-Müller S, End A and Zeillinger R: Biochip-based detection
of KRAS mutation in non-small cell lung cancer. Int J Mol Sci.
12:8530–8538. 2011. View Article : Google Scholar
|
|
16
|
Shames DS, Girard L, Gao B, Sato M, Lewis
CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, et al: A
genome-wide screen for promoter methylation in lung cancer
identifies novel methylation markers for multiple malignancies.
PLoS Med. 3:e4862006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bognar CL, Simon SD, Gansl RC, Abramoff R,
Aisen M, Lopes Junior Gde L, Smaletz O, Peres SV and Tabacof J: The
impact of erlotinib use in non-small-cell lung cancer patients
treated in a private reference general hospital and in a private
cancer clinic from 2005 to 2011. Einstein (Sao Paulo). 13:215–220.
2015.In English, Portuguese. View Article : Google Scholar
|
|
18
|
Moravcikova E, Krepela E, Prochazka J,
Benkova K and Pauk N: Differential sensitivity to apoptosome
apparatus activation in non-small cell lung carcinoma and the lung.
Int J Oncol. 44:1443–1454. 2014.PubMed/NCBI
|
|
19
|
Wang BY, Cao J, Chen JW and Liu QY:
Triptolide induces apoptosis of gastric cancer cells via inhibiting
the overexpression of MDM2. Med Oncol. 31:2702014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shao H, Ma J, Guo T and Hu R: Triptolide
induces apoptosis of breast cancer cells via a mechanism associated
with the Wnt/β-catenin signaling pathway. Exp Ther Med. 8:505–508.
2014.PubMed/NCBI
|
|
21
|
Ding X, Zhang B, Pei Q, Pan J, Huang S,
Yang Y, Zhu Z, Lv Y and Zou X: Triptolide induces apoptotic cell
death of human cholangiocarcinoma cells through inhibition of
myeloid cell leukemia-1. BMC Cancer. 14:2712014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rothschild SI: microRNA therapies in
cancer. Mol Cell Ther. 2:72014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li JS and Yao ZX: MicroRNAs: novel
regulators of oligodendrocyte differentiation and potential
therapeutic targets in demyelination-related diseases. Mol
Neurobiol. 45:200–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pan X, Wang ZX and Wang R: MicroRNA-21: A
novel therapeutic target in human cancer. Cancer Biol Ther.
10:1224–1232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gong B, Liu WW, Nie WJ, Li DF, Xie ZJ, Liu
C, Liu YH, Mei P and Li ZJ: MiR-21/RASA1 axis affects malignancy of
colon cancer cells via RAS pathways. World J Gastroenterol.
21:1488–1497. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Y, Meng H, Peng Q, Yang X, Gan R,
Zhao L, Chen Z, Lu J and Meng QH: Downregulation of microRNA-21
expression restrains non-small cell lung cancer cell proliferation
and migration through upregulation of programmed cell death 4.
Cancer Gene Ther. 22:23–29. 2015. View Article : Google Scholar
|
|
27
|
Li H, Hui L, Xu W, Shen H, Chen Q, Long L
and Zhu X: Triptolide modulates the sensitivity of K562/A02 cells
to adriamycin by regulating miR-21 expression. Pharm Biol.
50:1233–1240. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bunney TD and Katan M: Phosphoinositide
signalling in cancer: Beyond PI3K and PTEN. Nat Rev Cancer.
10:342–352. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K
and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN
and promotes growth and invasion in non-small cell lung cancer
(NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP,
Wang SH, Liang X and Lu CX: PTEN inhibits the migration and
invasion of HepG2 cells by coordinately decreasing MMP expression
via the PI3K/Akt pathway. Oncol Rep. 23:1593–1600. 2010.PubMed/NCBI
|
|
31
|
Poliseno L and Pandolfi PP: PTEN ceRNA
networks in human cancer. Methods. 77–78:41–50. 2015. View Article : Google Scholar
|
